
Why Cutting Leadership Support In Chaotic Times Is A Strategic Mistake
getty
'If the world's on fire, don't hand your leaders a smaller hose.'
Predictability is the business sweet spot. In a perfect world, strategy follows logic, market conditions hold steady and leadership decisions are made with clean data and clear visibility. But that world no longer exists—and may never return.
Today's senior leaders are navigating a swirling fog of global ambiguity. Not the normal kind, but a real shaking of global economic patterns and alliances.
The political and economic rules they used to rely on are shifting. Predictable patterns—quarterly forecasts, regional trends, even internal team dynamics—have gone sideways. The sense of rhythm, the ability to plan three steps ahead, has eroded.
And when predictability disappears, so does something else: peak performance.
Because decision-making at the top isn't just about data or instinct—it's about mental sharpness. Emotional clarity. The ability to think fast under pressure and still sleep at night. That kind of leadership thrives on stability. It needs a runway. It needs rhythm. But when predictability breaks, something else creeps in. Quietly. Subtly.
Ambiguity. And its two enablers: indecision and wait-and-see.
These are not benign forces. They are corrosive. They slow teams, stall momentum and leave high-potential leaders paralyzed just when their clarity is needed most. And the corporate reflex in times like this? Cut costs. Delay programs. 'Let's ride out the storm first.'
That instinct might be understandable, but it's deeply misguided. Because when you pause investment in your leaders during uncertainty, you're not just saving money. You're creating risk.
I've Lived In The Most Extreme Fog
I know what it's like to lead through ambiguity—not from a whiteboard, but from inside the storm.
Personal: In 2009, I took my first expat assignment in Japan. Not long after, my wife underwent emergency surgery and spent five hard months in the hospital. I had an eight-year-old daughter at home, asking questions I didn't always know how to answer. For two of those months, the hospital wouldn't even let her visit.
I was navigating a new country, a new leadership role and a family reality held together by duct tape and denial.
National Catastrophe: Then came the earthquake. On March 11, 2011, the ground shook, the sea surged and the nuclear reactors in Fukushima failed. My son was not yet a year old. He was a premature baby who needed formula—formula that required clean water. The doctor told us, 'Don't use the tap.'
So, I rode my bike in 10-mile loops across Tokyo, searching for bottled water that no longer existed.
Political: And just as the aftershocks began to fade, we moved to Korea, on the very day Kim Jong-un took power.
Weeks later, North Korea shelled Yeonpyeong Island. Tensions were high. One U.S. general pulled me aside in what was supposed to be a casual chat and asked, 'Do you know what to do if the shelling reaches Seoul?'
That wasn't an abstraction. It was a standing thought I carried into every meeting, every coaching session, every dinner with my team.
I had to lead through that.
And here's what I can tell you with absolute certainty: In that fog, I didn't need more dashboards or HQ pep talks. I needed someone to talk to. A second set of ears. A coach. A guide. Someone who could hold space for the impossible questions without judgment or consequence.
But I didn't have that.
So, I stewed. I second-guessed. I carried weight I didn't have to—alone.
Support doesn't remove the fog. But it gives you enough visibility to move. And when you're operating outside your cultural comfort zone, with geopolitical chaos around you and personal life on the brink? That clarity is everything.
The Cost Of Withholding The Compass
When the world gets messy, the instinct is to conserve—to delay investment, pause programs and hope for calmer skies. But leadership doesn't stop during turbulence. It gets harder. And here's the paradox: Just when your leaders need the most support, many companies pull it away. They cut coaching. Cancel development programs. Tell their most senior decision-makers to 'just hang tight.'
But ambiguity doesn't wait. Neither do markets. And indecision—especially at the top—gets expensive fast. You don't need to flood your leaders with more noise. You need to give them clarity. Space. Tools. A sounding board who isn't in the chain of command. Because if you want smart decisions in complex times, you can't starve the decision-makers.
In times of ambiguity, cutting leadership support is like flying into fog and turning off the radar.
Three Principles For Leading In The Fog
1. To The Boss: Don't scrimp on leadership development—especially coaching.
When things are most uncertain, your leaders need sounding boards, accountability partners and wise counsel. Coaching is not a perk—it's protective infrastructure.
2. To The Leader: Recognize the complexity. It's not just culture and quarterly goals—it's geopolitical volatility, economic turbulence and psychological strain.
Beware of isolation. Keep your mentors close. Keep your coaches closer.
3. To The Team Leader: Your team is watching your body language more than your briefings. Bring confidence, but also bring reality.
Create space for honest conversation about uncertainty. Ask how they're processing the world around them. Because no matter how experienced you are, they know the local ecosystem better than you do—and you can't lead it well without their insight.
Final Thoughts
Remember: Investing in leadership development and coaching during stable times is easy—it fits the budget and the narrative. But real leadership is tested when the future is unclear and the stakes are high. That's when support matters most.
Cutting resources in those moments may feel fiscally responsible, but it strips leaders of the very tools they need to navigate complexity, make sound decisions and keep teams aligned.
Don't expect clarity from the same leaders you just left in the dark.
Forbes Coaches Council is an invitation-only community for leading business and career coaches. Do I qualify?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes to Executive Leadership Team
Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, senior leaders from across the Coloplast Group have worked together to finalise the new Coloplast Group strategy, which will be communicated internally and externally in early September following approval by the Board of Directors. 'Our new strategy is centered around our customers. We will create and deliver the best customer experience for our users, patients and clinicians across our offering of products, support and services. Our ambition is to set the standard of care, to lead the market and to win!' says Lars Rasmussen, interim CEO of Coloplast. 'To deliver value for our customers, shareholders and more, we must evolve. That means putting the customer at the centre of everything we do. It also means delivering a step change in innovation to solidify our position as the innovation leader in our industry,' says Lars. During the current strategy period, the Coloplast Group has expanded with the addition of Atos Medical and Kerecis. Effective immediately, the company will organise its businesses into two distinct business units: Chronic Care and Acute Care. This structure allows the company to respect the differences in market dynamics, customer needs, patient pathways and business models, and it creates the needed structure to execute on the company's 2030 strategy. Changes to Chronic CareEffective immediately, a new Chronic Care Commercial business unit is being established. This will include the existing Chronic Care sales regions as well as relevant Chronic Care commercial functions. Given the chronic nature of most patients served by Atos Medical, the Voice & Respiratory Care business, Atos will also become part of the new Chronic Care Commercial business unit. To deliver a step change in innovation and bring new products faster to market, a stand-alone Chronic Care R&D function is also being established. 'As we are making significant changes to the Chronic Care setup, the Board and Executive Vice President Nicolai Buhl have mutually agreed that Nicolai will leave Coloplast. Nicolai has achieved great things in his time with Coloplast as a senior leader within Wound Care as well as Chronic Care. On behalf of the Board and the ELT, I want to thank Nicolai for his dedication and leadership,' says Lars. Caroline Vagner Rosenstand will take on the role as Executive Vice President of Chronic Care Commercial. 'Caroline is an experienced leader with a great track record of building followership, defining and executing on commercial strategies and delivering results,' says Lars. On November 1st, Rasmus Just will step into the role of Executive Vice President of Chronic Care R&D. Rasmus Just brings valuable experience from his five years at Coloplast, where he held several leadership roles within innovation, before continuing his career for the past 3 years in Device R&D at Novo Nordisk. 'Rasmus is an experienced R&D leader with a strong technology and business focus, and we are happy to welcome him back to Coloplast,' says Lars. Introducing Acute CareThe new Acute Care business unit includes Interventional Urology (IU), Advanced Wound Dressings (AWD) and Kerecis. These treatment areas are characterised by premium products like Coloplast's penile implants, the Kerecis fish skin portfolio and our wound dressings. Most of these products and technologies are used in specialised private clinics or in the hospital setting, where innovation and clinical outcomes are critical. Effective immediately, the AWD and Kerecis commercial organisations are being merged into a new Wound & Tissue Repair organisation within Acute Care. The goal is to become an innovation leader in this area and to create a strong global footprint by merging these two complementary businesses. Wound & Tissue Repair will be led by Executive Vice President Fertram Sigurjonsson. 'With Kerecis, Fertram has built a company with strong innovation capability and growth potential based on a unique technology. Bringing these capabilities together in a new Wound & Tissue Repair unit represents a significant milestone for our AWD and Kerecis businesses,' says Lars. There are no changes to the IU business, which will continue under the leadership of Executive Vice President Tommy Johns. 'I would like to congratulate Caroline, Fertram and Rasmus on their new roles,' ends Lars. The new ELT Lars Rasmussen, interim CEO Anders Lonning-Skovgaard, EVP & CFO Allan Rasmussen, EVP Global Operations Dorthe Rønnau, EVP People & Culture Caroline Vagner Rosenstand, EVP Chronic Care Commercial Rasmus Just, EVP Chronic Care R&D (start date 1 November) Fertram Sigurjonsson, EVP Wound & Tissue Repair Tommy Johns, EVP Interventional Urology Lars Rasmussen, interim President and CEO, and Anders Lonning-Skovgaard, Executive Vice President and CFO, constitute the management registered with the Danish Business Authority. ContactsPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@ Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 2458Email: dkadim@ Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 3266Email: dkkhu@ Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 2981Email: dksdk@ This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound and Skin Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, 05_2025_Coloplast_announces_changes_to_ELTSign in to access your portfolio
Yahoo
an hour ago
- Yahoo
SoftBank's Son backs ally Tan with $2 billion Intel investment
By Sam Nussey, Fanny Potkin and Anton Bridge TOKYO (Reuters) -When Lip-Bu Tan stepped down from the SoftBank Group board in 2022 at a time when the Japanese company was grappling with soured investments, his parting message offered advice on how Masayoshi Son's conglomerate could strengthen its business. Three years later, a resurgent SoftBank has made a show of support by taking a $2 billion stake in Intel as Tan, now the storied American company's CEO, seeks to turn around the embattled chipmaker. Tan took Intel's top job in March and is driving restructuring at the company, which lost out to Nvidia in artificial intelligence chips and whose foundry business is struggling. "This is really a vote of confidence of Masa in the turnaround materialising over the coming years," said Rolf Bulk, an analyst at New Street Research. "For Intel, the investment makes it more likely that SoftBank could be a potential client to Intel in the future." The two men have a long-standing relationship. "Masa and I have worked closely together for decades, and I appreciate the confidence he has placed in Intel with this investment," Tan said in a statement. In addition to his time on SoftBank's board, Tan became chairman of chip startup SambaNova, which received backing from SoftBank's Vision Fund. "Masa is brilliant; he's a visionary. But he still needs people to provide safeguards, give him advice, and make him even more successful," Tan wrote in his statement on leaving the SoftBank board. Son, 68, is known as a savvy political operator, appearing publicly with U.S. President Donald Trump twice in the months following the presidential election. He has close relationships with leading tech entrepreneurs such as Jensen Huang, CEO of Nvidia, in which SoftBank has a stake. Last week Tan, 65, met with Trump, who days earlier had called on him to resign due to his ties to Chinese firms. Washington is in talks to take a 10% stake in Intel, Bloomberg has reported. "SoftBank's investment helps but it is not what is going to move the dial for Intel," said Amir Anvarzadeh of Asymmetric Advisors. "It's more to maintain this very good relationship he has with Trump," he said. BACK ON THE OFFENSIVE Son is making splashy investments again after some underperforming tech bets forced a period of retrenchment, with the conglomerate pursuing a $500 billion U.S. data centre venture with OpenAI, the maker of ChatGPT. SoftBank has acquired a former electric vehicle factory from Foxconn in Ohio as it looks to advance its Stargate data center project. Arm, which is controlled by SoftBank, plans to make its own chips, and the Japanese conglomerate also acquired chipmaker Graphcore last year. SoftBank's shares have been on a tear, boosted by positive sentiment around its AI investments. "The $2 billion investment should be viewed more as a strategic stake rather than a financial one," said Nori Chiou, investment director at White Oak Capital Partners. "In the world of cutting-edge semiconductor manufacturing, only capital commitments in the $30 billion–$40 billion range carry true commercial weight," he said. Industry experts say Tan still faces a mountain to climb to turn around Intel, which has suffered from years of management missteps. "It is Masa making a contrarian bet but one where I think the downside risk is fairly limited," said Bulk of New Street Research.
Yahoo
an hour ago
- Yahoo
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 26.2%
Amidst easing trade tensions and a renewed tariff pause between the U.S. and China, Asian markets have shown resilience with notable gains in major indices such as Japan's Nikkei 225 and China's CSI 300. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities to capitalize on potential market inefficiencies, especially when stocks are estimated to be trading at significant discounts. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Xi'an NovaStar Tech (SZSE:301589) CN¥157.16 CN¥311.16 49.5% Nan Juen International (TPEX:6584) NT$228.00 NT$453.12 49.7% Matsuya R&DLtd (TSE:7317) ¥717.00 ¥1427.08 49.8% Lotes (TWSE:3533) NT$1345.00 NT$2677.95 49.8% Kolmar Korea (KOSE:A161890) ₩79500.00 ₩155064.18 48.7% King Yuan Electronics (TWSE:2449) NT$141.00 NT$279.98 49.6% Kadokawa (TSE:9468) ¥3679.00 ¥7271.24 49.4% Inspur Digital Enterprise Technology (SEHK:596) HK$10.19 HK$20.22 49.6% Heartland Group Holdings (NZSE:HGH) NZ$0.81 NZ$1.60 49.3% GCH Technology (SHSE:688625) CN¥34.22 CN¥68.10 49.7% Click here to see the full list of 266 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. We're going to check out a few of the best picks from our screener tool. Asian Star Anchor Chain Jiangsu Overview: Asian Star Anchor Chain Co., Ltd. Jiangsu, with a market cap of CN¥10.93 billion, manufactures and sells anchor chains, marine mooring chains, and related accessories globally through its subsidiaries. Operations: Asian Star Anchor Chain Co., Ltd. Jiangsu generates revenue primarily through the production and distribution of anchor chains, marine mooring chains, and related accessories on a global scale. Estimated Discount To Fair Value: 23.8% Asian Star Anchor Chain Jiangsu is trading at CN¥11.39, significantly undervalued compared to its estimated fair value of CN¥14.95, with a discount of over 20%. The company's earnings are forecast to grow at 27.3% annually, outpacing the Chinese market's average growth rate of 23.9%. Revenue growth is also strong at 24.9% per year, surpassing the market's 12.8%, although its dividend track record remains unstable. Insights from our recent growth report point to a promising forecast for Asian Star Anchor Chain Jiangsu's business outlook. Delve into the full analysis health report here for a deeper understanding of Asian Star Anchor Chain Jiangsu. JWIPC Technology Overview: JWIPC Technology Co., Ltd. focuses on researching, developing, and manufacturing IoT hardware solutions with a market cap of CN¥14.27 billion. Operations: The company's revenue segments include Industry Terminal at CN¥2.59 billion, ICT Infrastructure at CN¥637.74 million, Industrial Internet of Things at CN¥232.23 million, and Intelligent Computing Business at CN¥477.98 million. Estimated Discount To Fair Value: 26.2% JWIPC Technology is trading at CN¥59.77, offering a significant discount of 26.2% below its estimated fair value of CN¥80.98. The company's earnings have shown robust growth, increasing by 256.2% over the past year, with future earnings projected to grow significantly at 34.4% annually—outpacing the Chinese market's average rate of 23.9%. Recent half-year results showed improved sales and net income compared to the previous year, indicating strong cash flow potential despite a forecasted low return on equity in three years (15.2%). Our earnings growth report unveils the potential for significant increases in JWIPC Technology's future results. Get an in-depth perspective on JWIPC Technology's balance sheet by reading our health report here. Co-Tech Development Overview: Co-Tech Development Corporation, with a market cap of NT$46.57 billion, produces and sells copper foil for the printed circuit board industry in Taiwan and China. Operations: The company's revenue is derived from the production and sale of copper foil, amounting to NT$7.23 billion. Estimated Discount To Fair Value: 19.1% Co-Tech Development is trading at NT$184.5, approximately 19.1% below its estimated fair value of NT$227.94, suggesting undervaluation based on cash flows. Despite a volatile share price recently, the company's earnings are forecast to grow significantly by 64% annually, outpacing the Taiwanese market's average growth rate of 15.5%. Recent earnings results showed increased sales but decreased net income year-on-year, reflecting some operational challenges amid leadership changes and strategic committee appointments in June 2025. Our growth report here indicates Co-Tech Development may be poised for an improving outlook. Click here to discover the nuances of Co-Tech Development with our detailed financial health report. Taking Advantage Reveal the 266 hidden gems among our Undervalued Asian Stocks Based On Cash Flows screener with a single click here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:601890 SZSE:001339 and TPEX:8358. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data